Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.76 |
| ▸ | CASP7 | P55210 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.76 |
| ▸ | VDR | P11473 | 3/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | BLM | P54132 | 2/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | MDM4 | O15151 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697152 | 1.00 | GPBAR1 (0.76) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL235607 | 0.91 | GPBAR1 (0.77) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL235606 | 0.91 | GPBAR1 (0.77) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL26670009 | 0.91 | GPBAR1 (0.77) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL476518 | 0.88 | GPBAR1 (0.73) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL5577556 | 0.88 | GPBAR1 (0.73) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL476519 | 0.88 | GPBAR1 (0.73) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL5577551 | 0.88 | GPBAR1 (0.73) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL7996290 | 0.87 | GPBAR1 (0.72) | GPBAR1CASP7HSD17B10TDP1EPHA2 | |
| SCHEMBL5919526 | 0.87 | GPBAR1 (0.76) | GPBAR1CASP7HSD17B10TDP1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964808-A | Solid catalyst component, preparation method, catalyst system and application | 中国石油化工股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117964807-A | Solid catalyst component for olefin polymerization, preparation method, catalyst system and application | 中国石油化工股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20160206749-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | MARINA BIOTECH, INC. (US) | 2016-07-21 | — | — | US | claimed |
| WO-2015065983-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-05-07 | — | — | WO | claimed |
| EP-2739286-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2014-06-11 | — | — | EP | claimed |
| WO-2013020108-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | WO | claimed |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | US | claimed |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-10-23 | — | — | US | claimed |
| EP-1773998-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | Nastech Pharmaceutical Company Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006019430-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-20240216364-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | ENYO PHARMA (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240173317-A1 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1773998-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | Nastech Pharmaceutical Company Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006019430-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2004011528-A1 | DIAMINE COMPOUND, POLYAMIC ACID, IMIDE POLYMER, LIQUID CRYSTAL ALIGNMENT AGENT AND LIQUID CRYSTAL DISPLAY | JSR CORPORATION (JP) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173317-A1 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | GPBAR1 17/4885CASP7 2610/4885HSD17B10 189/4885 |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | SNRPE, LDLR, SNRPA | GPBAR1 1437/4885CASP7 2790/4885HSD17B10 2788/4885 |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | GPBAR1 9/4885CASP7 2503/4885HSD17B10 235/4885 |
| US-20160206749-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | SNRPE, SREBF2, SREBF1 | GPBAR1 1177/4885CASP7 3322/4885HSD17B10 2286/4885 |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | GPBAR1 9/4885CASP7 2503/4885HSD17B10 235/4885 |
| US-20240216364-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | TLR3, NR1H4, TLR9 | GPBAR1 7/4885CASP7 3162/4885HSD17B10 1721/4885 |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | SNRPE, SREBF2, SREBF1 | GPBAR1 1177/4885CASP7 3322/4885HSD17B10 2286/4885 |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | SLC10A2, SLC10A1, NR1H4 | GPBAR1 5/4885CASP7 3038/4885HSD17B10 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.